(TGTX) TG Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 6.529m USD | Total Return: 12.7% in 12m

Monoclonal Antibodies, Multiple Sclerosis, BTK Inhibitors
Total Rating 42
Safety 36
Buy Signal 0.29
Biotechnology
Industry Rotation: -18.1
Market Cap: 6.53B
Avg Turnover: 69.6M
Risk 3d forecast
Volatility62.9%
VaR 5th Pctl9.09%
VaR vs Median-15.9%
Reward TTM
Sharpe Ratio0.40
Rel. Str. IBD80.4
Rel. Str. Peer Group54.8
Character TTM
Beta0.935
Beta Downside0.163
Hurst Exponent0.355
Drawdowns 3y
Max DD76.95%
CAGR/Max DD0.15
CAGR/Mean DD0.36
EPS (Earnings per Share) EPS (Earnings per Share) of TGTX over the last years for every Quarter: "2021-03": -0.69, "2021-06": -0.59, "2021-09": -0.65, "2021-12": -0.7, "2022-03": -0.51, "2022-06": -0.3, "2022-09": -0.26, "2022-12": -0.39, "2023-03": -0.28, "2023-06": -0.34, "2023-09": 0.73, "2023-12": -0.1, "2024-03": -0.07, "2024-06": 0.04, "2024-09": 0.02, "2024-12": 0.15, "2025-03": 0.03, "2025-06": 0.17, "2025-09": 2.43, "2025-12": 0.14, "2026-03": 0.1791,
EPS CAGR: 57.24%
EPS Trend: 55.4%
Last SUE: -0.12
Qual. Beats: 0
Revenue Revenue of TGTX over the last years for every Quarter: 2021-03: 0.793, 2021-06: 1.545, 2021-09: 2.03, 2021-12: 2.321, 2022-03: 2.016, 2022-06: 0.594, 2022-09: 0.094, 2022-12: 0.08, 2023-03: 7.803, 2023-06: 16.074, 2023-09: 165.815, 2023-12: 43.971, 2024-03: 63.474, 2024-06: 73.466, 2024-09: 83.879, 2024-12: 108.185, 2025-03: 120.856, 2025-06: 141.148, 2025-09: 161.709, 2025-12: 192.574, 2026-03: 204.918,
Rev. CAGR: 375.06%
Rev. Trend: 81.5%
Last SUE: 0.71
Qual. Beats: 0

Warnings

Beneish M-Score 1.00 > -1.5 - likely earnings manipulation

Tailwinds

Confidence

Description: TGTX TG Therapeutics

TG Therapeutics Inc (TGTX) is a commercial-stage biopharmaceutical firm specializing in therapies for B-cell mediated diseases, primarily multiple sclerosis (MS) and B-cell malignancies. Its lead commercial product, BRIUMVI, is an anti-CD20 monoclonal antibody approved for treating various relapsing forms of MS in adults. The companys development model relies on a mix of internal research and strategic licensing agreements with international partners to expand its pipeline of kinase inhibitors and bispecific antibodies.

The biotechnology sector often requires high research and development (R&D) expenditure and navigating rigorous FDA regulatory pathways before achieving commercial revenue. TGTX’s business model centers on the glycoengineering of antibodies, a process designed to enhance the potency of biologics by modifying their carbohydrate structures to improve immune system interaction. Beyond its primary MS focus, the company is investigating BTK inhibitors and CD47/CD19 bispecific antibodies to address unmet needs in oncology.

For a deeper look into the companys valuation metrics and financial health, consider reviewing the data available on ValueRay. TG Therapeutics operates out of Morrisville, North Carolina, and maintains a global presence through its distribution and licensing networks.

Headlines to Watch Out For
  • Briumvi adoption rates in the competitive multiple sclerosis market drive revenue growth
  • Expansion into subcutaneous administration improves long-term product positioning and patient convenience
  • International commercialization partnerships determine royalty income and global market penetration
  • Research and development expenses for bispecific antibodies impact overall cash burn rates
  • Medicare pricing negotiations and reimbursement policies influence net product realized price
Piotroski VR‑10 (Strict) 5.0
Net Income: 461.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.01 > 0.02 and ΔFCF/TA 8.38 > 1.0
NWC/Revenue: 128.5% < 20% (prev 125.3%; Δ 3.15% < -1%)
CFO/TA -0.01 > 3% & CFO -14.0m > Net Income 461.9m
Net Debt (311.3m) to EBITDA (156.9m): 1.98 < 3
Current Ratio: 5.81 > 1.5 & < 3
Outstanding Shares: last quarter (160.1m) vs 12m ago -1.66% < -2%
Gross Margin: 83.04% > 18% (prev 0.87%; Δ 8.22k% > 0.5%)
Asset Turnover: 64.09% > 50% (prev 58.84%; Δ 5.25% > 0%)
Interest Coverage Ratio: 5.67 > 6 (EBITDA TTM 156.9m / Interest Expense TTM 27.6m)
Altman Z'' 1.38
A: 0.59 (Total Current Assets 1.09b - Total Current Liabilities 187.1m) / Total Assets 1.53b
B: -0.69 (Retained Earnings -1.06b / Total Assets 1.53b)
C: 0.14 (EBIT TTM 156.6m / Avg Total Assets 1.09b)
D: -1.12 (Book Value of Equity -1.06b / Total Liabilities 945.7m)
Altman-Z'' Score: 1.38 = BB
Beneish M 1.00
DSRI: 1.14 (Receivables 392.0m/190.1m, Revenue 700.3m/386.4m)
GMI: 1.05 (GM 83.04% / 87.43%)
AQI: 35.61 (AQ_t 0.28 / AQ_t-1 0.01)
SGI: 1.81 (Revenue 700.3m / 386.4m)
TATA: 0.31 (NI 461.9m - CFO -14.0m) / TA 1.53b)
Beneish M-Score: 18.56 (Cap -4..+1) = D
What is the price of TGTX shares? As of May 20, 2026, the stock is trading at USD 39.43 with a total of 1,194,876 shares traded.
Over the past week, the price has changed by -7.31%, over one month by +6.68%, over three months by +33.84% and over the past year by +12.72%.
Is TGTX a buy, sell or hold? TG Therapeutics has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy TGTX.
  • StrongBuy: 5
  • Buy: 1
  • Hold: 0
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the TGTX price?
Analysts Target Price 48.1 22.1%
TG Therapeutics (TGTX) - Fundamental Data Overview as of 16 May 2026
P/E Trailing = 14.9126
P/E Forward = 33.0033
P/S = 8.916
P/B = 11.2569
P/EG = 1.6144
Revenue TTM = 700.3m USD
EBIT TTM = 156.6m USD
EBITDA TTM = 156.9m USD
Long Term Debt = 245.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.82m USD (from shortTermDebt, last quarter)
Debt = 753.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 311.3m USD (from netDebt column, last quarter)
Enterprise Value = 6.77b USD (6.53b + Debt 753.6m - CCE 514.4m)
Interest Coverage Ratio = 5.67 (Ebit TTM 156.6m / Interest Expense TTM 27.6m)
EV/FCF = -476.9x (Enterprise Value 6.77b / FCF TTM -14.2m)
FCF Yield = -0.21% (FCF TTM -14.2m / Enterprise Value 6.77b)
FCF Margin = -2.03% (FCF TTM -14.2m / Revenue TTM 700.3m)
Net Margin = 65.95% (Net Income TTM 461.9m / Revenue TTM 700.3m)
Gross Margin = 83.04% ((Revenue TTM 700.3m - Cost of Revenue TTM 118.7m) / Revenue TTM)
Gross Margin QoQ = 83.65% (prev 80.19%)
Tobins Q-Ratio = 4.43 (Enterprise Value 6.77b / Total Assets 1.53b)
Interest Expense / Debt = 1.02% (Interest Expense 7.67m / Debt 753.6m)
Taxrate = 2.88% (586k / 20.4m)
NOPAT = 152.1m (EBIT 156.6m * (1 - 2.88%))
Current Ratio = 5.81 (Total Current Assets 1.09b / Total Current Liabilities 187.1m)
Debt / Equity = 1.29 (Debt 753.6m / totalStockholderEquity, last quarter 583.1m)
Debt / EBITDA = 1.98 (Net Debt 311.3m / EBITDA 156.9m)
 Debt / FCF = -21.94 (negative FCF - burning cash) (Net Debt 311.3m / FCF TTM -14.2m)
 Total Stockholder Equity = 528.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 42.27% (Net Income 461.9m / Total Assets 1.53b)
RoE = 87.36% (Net Income TTM 461.9m / Total Stockholder Equity 528.7m)
RoCE = 20.22% (EBIT 156.6m / Capital Employed (Equity 528.7m + L.T.Debt 245.6m))
RoIC = 20.12% (NOPAT 152.1m / Invested Capital 755.9m)
WACC = 8.41% (E(6.53b)/V(7.28b) * Re(9.27%) + D(753.6m)/V(7.28b) * Rd(1.02%) * (1-Tc(0.03)))
Discount Rate = 9.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 33.33 | Cagr: 5.11%
 [DCF] Fair Price = unknown (Cash Flow -14.2m)
 EPS Correlation: 55.39 | EPS CAGR: 57.24% | SUE: -0.12 | # QB: 0
Revenue Correlation: 81.50 | Revenue CAGR: 375.1% | SUE: 0.71 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.46 | Chg30d=+33.81% | Revisions=-20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.43 | Chg30d=+31.62% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=1.61 | Chg30d=+29.79% | Revisions=+33% | GrowthEPS=-41.8% | GrowthRev=+52.6%
EPS next Year (2027-12-31): EPS=2.73 | Chg30d=+10.79% | Revisions=-33% | GrowthEPS=+69.1% | GrowthRev=+30.3%
[Analyst] Revisions Ratio: +33%